Laura M Jacobsen1, Brittney N Newby2, Daniel J Perry2, Amanda L Posgai2, Michael J Haller1, Todd M Brusko3. 1. Department of Pediatrics, College of Medicine, University of Florida Diabetes Institute, Gainesville, FL, USA. 2. Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida Diabetes Institute, 1275 Center Drive, Biomedical Sciences Building J-589, Box 100275, Gainesville, FL, 32610, USA. 3. Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida Diabetes Institute, 1275 Center Drive, Biomedical Sciences Building J-589, Box 100275, Gainesville, FL, 32610, USA. tbrusko@ufl.edu.
Abstract
PURPOSE OF REVIEW: The immunosuppressive agent cyclosporine was first reported to lower daily insulin dose and improve glycemic control in patients with new-onset type 1 diabetes (T1D) in 1984. While renal toxicity limited cyclosporine's extended use, this observation ignited collaborative efforts to identify immunotherapeutic agents capable of safely preserving β cells in patients with or at risk for T1D. RECENT FINDINGS: Advances in T1D prediction and early diagnosis, together with expanded knowledge of the disease mechanisms, have facilitated trials targeting specific immune cell subsets, autoantigens, and pathways. In addition, clinical responder and non-responder subsets have been defined through the use of metabolic and immunological readouts. Herein, we review emerging T1D biomarkers within the context of recent and ongoing T1D immunotherapy trials. We also discuss responder/non-responder analyses in an effort to identify therapeutic mechanisms, define actionable pathways, and guide subject selection, drug dosing, and tailored combination drug therapy for future T1D trials.
PURPOSE OF REVIEW: The immunosuppressive agent cyclosporine was first reported to lower daily insulin dose and improve glycemic control in patients with new-onset type 1 diabetes (T1D) in 1984. While renal toxicity limited cyclosporine's extended use, this observation ignited collaborative efforts to identify immunotherapeutic agents capable of safely preserving β cells in patients with or at risk for T1D. RECENT FINDINGS: Advances in T1D prediction and early diagnosis, together with expanded knowledge of the disease mechanisms, have facilitated trials targeting specific immune cell subsets, autoantigens, and pathways. In addition, clinical responder and non-responder subsets have been defined through the use of metabolic and immunological readouts. Herein, we review emerging T1D biomarkers within the context of recent and ongoing T1D immunotherapy trials. We also discuss responder/non-responder analyses in an effort to identify therapeutic mechanisms, define actionable pathways, and guide subject selection, drug dosing, and tailored combination drug therapy for future T1D trials.
Authors: Vimukthi Pathiraja; Janine P Kuehlich; Peter D Campbell; Balasubramanian Krishnamurthy; Thomas Loudovaris; P Toby H Coates; Thomas C Brodnicki; Philip J O'Connell; Katherine Kedzierska; Christine Rodda; Philip Bergman; Erin Hill; Anthony W Purcell; Nadine L Dudek; Helen E Thomas; Thomas W H Kay; Stuart I Mannering Journal: Diabetes Date: 2014-08-25 Impact factor: 9.461
Authors: Stephen E Gitelman; Peter A Gottlieb; Mark R Rigby; Eric I Felner; Steven M Willi; Lynda K Fisher; Antoinette Moran; Michael Gottschalk; Wayne V Moore; Ashley Pinckney; Lynette Keyes-Elstein; Sudeepta Aggarwal; Deborah Phippard; Peter H Sayre; Linna Ding; Jeffrey A Bluestone; Mario R Ehlers Journal: Lancet Diabetes Endocrinol Date: 2013-08-28 Impact factor: 32.069
Authors: I Truyen; P De Pauw; P N Jørgensen; C Van Schravendijk; O Ubani; K Decochez; E Vandemeulebroucke; I Weets; R Mao; D G Pipeleers; F K Gorus Journal: Diabetologia Date: 2005-10-07 Impact factor: 10.122
Authors: D Mokhtari; A Al-Amin; K Turpaev; T Li; O Idevall-Hagren; J Li; A Wuttke; R G Fred; P Ravassard; R Scharfmann; A Tengholm; N Welsh Journal: Diabetologia Date: 2013-03-05 Impact factor: 10.122
Authors: Anette G Ziegler; Marian Rewers; Olli Simell; Tuula Simell; Johanna Lempainen; Andrea Steck; Christiane Winkler; Jorma Ilonen; Riitta Veijola; Mikael Knip; Ezio Bonifacio; George S Eisenbarth Journal: JAMA Date: 2013-06-19 Impact factor: 56.272
Authors: M N Weedon; A T Hattersley; K A Patel; R A Oram; S E Flanagan; E De Franco; K Colclough; M Shepherd; S Ellard Journal: Diabetes Date: 2016-04-05 Impact factor: 9.461
Authors: John A Todd; Paul R V Johnson; M Loredana Marcovecchio; Linda S Wicker; David B Dunger; Susan J Dutton; Sylwia Kopijasz; Claire Scudder Journal: Wellcome Open Res Date: 2020-03-20
Authors: Mateusz Gliwiński; Dorota Iwaszkiewicz-Grześ; Anna Wołoszyn-Durkiewicz; Monika Tarnowska; Magdalena Żalińska; Matylda Hennig; Hanna Zielińska; Anna Dukat-Mazurek; Joanna Zielkowska-Dębska; Maciej Zieliński; Anna Jaźwińska-Curyłło; Radosław Owczuk; Przemysława Jarosz-Chobot; Artur Bossowski; Agnieszka Szadkowska; Wojciech Młynarski; Natalia Marek-Trzonkowska; Grażyna Moszkowska; Janusz Siebert; Małgorzata Myśliwiec; Piotr Trzonkowski Journal: BMJ Open Diabetes Res Care Date: 2020-02
Authors: Laura M Jacobsen; Brian N Bundy; Madison N Greco; Desmond A Schatz; Mark A Atkinson; Todd M Brusko; Clayton E Mathews; Kevan C Herold; Stephen E Gitelman; Jeffrey P Krischer; Michael J Haller Journal: Diabetes Technol Ther Date: 2020-10-20 Impact factor: 6.118